賽生藥業控股有限公司 SciClone Pharmaceuticals (Holdings) Limited
Climate Impact & Sustainability Data (2020, 2021, 2022, 2023)
Reporting Period: 2020
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Challenging operating environment due to COVID-19 pandemic, uncertainties, risks and challenges confronted businesses and the macroeconomy.
Mitigation Strategies
- Effective product lifecycle management, progresses in commercialization of in-licensed products, expanded product pipeline, innovative business models (e.g., “Go-To-Patient” model).
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2021
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Single product concentration
Mitigation Strategies
- Expand product pipeline and build internal R&D capability
- Seek strategic cooperation with biotech companies
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2022
Environmental Metrics
Climate Goals & Targets
Medium-term Goals:
- License-in innovative assets in oncology and severe infection to fulfill unmet medical needs in China.
Short-term Goals:
- Consolidate patients, physicians and pharmacies onto the Hi-Doctor Platform to complete the closed-cycle of “internet hospital-prescription-DTP pharmacies-delivery” and increase GTP contribution for Zometa.
- Drive clinical evidence analysis and publication on Zadaxin in infectious diseases, including adjuvant for vaccines in the U.S., and expand therapy indications in oncology through combination therapy with PD-1/PD-L1.
- Advocate clinical adoption of Zometa in adjuvant setting for early breast cancer and leverage new treatment guidelines to promote Zometa.
- Commercial launch Danyelza and expand insurance coverage to address patient affordability.
- Enhance cooperation with partners, including Pfizer and Baxter.
- Complete more than 50% patient enrolment for Vaborem registration study in China.
- Initiate patient enrollment of STUDY 203 of Danyelza.
- Conduct interim analysis of REPLATINUM for RRx-001.
Environmental Challenges
- COVID-19 control measures and outbreaks in certain cities of China reduced patients’ hospital visits, impacting product sales.
- Global valuation plunge, cash crunch in biotech companies and appreciation of USD lowered net profit.
Mitigation Strategies
- Integrated internet hospitals into the unique “Go-To-Patient” (“GTP”) model to improve direct connection between physicians and patients and increase product accessibility.
- Mobilized global supply chain and established an emergency supply channel to ensure availability of Zadaxin during surge in demand.
- Developed outpatient infusion centers for Zometa in major cities.
- Incorporated Zometa into GTP model, promoting digital portal Healthy Bone Alliance and integrating services into Hi-Doctor platform to enhance patient access outside hospitals.
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2023
Environmental Metrics
Climate Goals & Targets
Environmental Challenges
- Relentless inflation, interest rate hikes, mounting international geopolitical tensions, and a waning recovery pace.
Mitigation Strategies
- Multiple measures to maintain the steady development of the Company’s core business